Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers

NCT03835013 · Completed

Last updated 2026-05-28

This clinical trial tests how different hormones (glucagon and exenatide) affect blood flow and heart function in healthy adult men by comparing them to a saline solution.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, single-blind basic-science study

Participants 26 people

Who can join Ages 18–40 · male only Healthy volunteers accepted.

Timeline Started 2019-02 · est. completion 2021-11

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT03835013 ↗

Description as written by the study sponsor.

The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, and combination into healthy male participants. Overall, the aim of the study is to further our understanding on the role these endogenous substances play (both in isolation and combination) in haemodynamic regulation.

Treatments tested

Saline 0.9% also known as Placebo Drug

Intravenous infusion of 0.9% saline
Glucagon (25ng/kg/min) also known as Glucagon Drug

Intravenous infusion of glucagon 25ng/kg/min
Glucagon (50ng/kg/min) also known as Glucagon Drug

Intravenous infusion of glucagon 50ng/kg/min
Exenatide Drug

Intravenous infusion of Exenatide (loading 50ng/min for 30 minutes followed by 25ng/min for 30 minutes

Main thing measured	Changes in haemodynamic parameters following intravenous infusion of 0.9% saline, glucagon, exenatide and their combination.
Sponsor	Cambridge University Hospitals NHS Foundation Trust
Conditions studied	Cardiovascular Diseases
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03835013 ↗